1. SPILF. Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires de l’adulte. Mise au point mai 2014. http://www.infectiologie.com
2. SPILF. Révision des recommandations de bonne pratique pour la prise encharge et la prévention des Infections Urinaires Associées aux Soins (IUAS) de l’adulte. mai 2015 http://www.infectiologie.com
3. Grabe M. et al. Guidelines on urological infections. European Association of Urology (EAU) 2014 update mars 2013 http://www.uroweb.org/gls/pdf/19%20Urological%20infections_LR.pdf
4. Gupta K. et al. International clinical practice guidelines of the treatment of acute uncomplicated cystitis and pyelonephritis in women: an 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin infect dis 2011; 52(5): e103-e120
5. Hooton TM. Uncomplicated urinary tract infection. N Engl J Med 2012; 366: 1028-37
6. Emonet S. et al. Infection urinaire de l’adulte. Rev Med Suisse 2011 ; 7 : 912-6
7. Francois A. et al. infections urinaires. 2013. Hôpitaux Universitaires de Genève (HUG) Département de Médecine Communautaires, de Premier Recours et des Urgences. http://www.hugge.ch/sites/interhug/files/structures/medecine_de_premier_recours/documents/infos_soignants/infections_urinaires_arce.pdf
8. Barber AE. et al. Urinary tract infections : current and emerging management strategies. Clin infect dis 2013; 57(5): 719-24
9. Hooton TM. et al. Acute uncomplicated cystitis and pyelonephritis in women. Up To date 7/02/2014 http://wwww.uptodate.com
10. Foxman B. Urinary tract infection syndromes. Occurrence, recurrence, bacteriology, risk factors and diseases burden. Infect Dis Clin N Am 2014; 28: 1-13
11. Trautner BW. et al. Approach to a positive urine culture in patient without urinary symptoms. Infect Dis Clin N Am 2014; 28: 15-31
12. Takhar SS. et al. Diagnosis and management of urinary tract infection in the emergency department and outpatient settings. Infect Dis Clin N Am 2014; 28: 33-48
13. Lane DR. et al. Diagnosis and management of urinary tract infections and pyelonephritis. Emerg Med Clin N Am 2011; 29: 539-552
14. Wang A. et al. Urinary tract infections. Prim Care Clin Office Pract 2013; 40: 687-706
15. Nicolle LE. Urinaty tract infection. Crit Care Clin 2013; 29: 699-715
16. Gupta K. et al. Management of urinary tract infection from multidrug-resistant organisms. Infect Dis Clin N Am 2014; 28: 49-59
17. Shepherd AK. et al. Management of urinary tract infections in the era of increasing antimicrobial resistance. Med Clin N Am 2013; 97: 737-57
18. Fournier D. et al. Alternatives to carbapemens in EBLSE-producing Escherichia coli infections. Med Mal Inf 2013 ; 43 : 62-6
19. ANSM. Caractérisation des antibiotiques considérés comme critiques. Novembre 2013 http://ansm.sante.fr
20. Hooton T M. Acute complicated cystitis and pyelonephritis. Up To date 30/05/2014 http://www.uptodate.com
21. Spoorenberg V. et al. Appropriate antibiotic use for patients with urinary tract infections reduces lengh of hospital stay. Clin Infect Dis 2014; 58(2): 164-9
22. Chapman AB. et al. Urinary tract infection in autosomal dominant polycystic kidney disease. Up To Date 20/03/2014 http://www.uptodate.com
23. Meyrier A. Renal and perinephric abscess. Up To date 20/06/2014 http://www.uptodate.com
24. Weintrob AC. et al. Emphysematous urinary tract infections. Up To date 07/10/2013 http://www.uptodate.com
25. Oteo J. et al. Parallel increase in community use of fosfomycine and resistance to fosfomycine in extensed-spectrum beta-lactamase (EBLSE)-producing Escherichia coli. J Antimicrob Chemother 2010; 65(11): 2459-63
26. High KP et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: an 2008 update by the Infectious Diseases society of America. Clin Infect dis 2009; 48: 149-71
27. Loeb M. et al. Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference. Infect Control Hosp Epidemiol 2001; 22: 120-4
28. Loeb M. et al. Effect of a multifaceted intervention on number of antimicrobial prescriptions for suspected urinary tract infections in residents of nursing homes: cluster randomized controlled trial. BMJ 2005; 331(7518):669
29. Juthani-Metha M. et al. Diagnostic accuracy of criteria for urinary tract infection in a cohort of nursing home residents. J Am Geriatr Soc 2007; 55: 1072-7
30. Stone ND. et al. Surveillance definitions of criteria for urinary tract infection in a cohort of nursing home resident. J Am Geriatr Soc 2007; 55(7): 1072-7
31. Oplinger M. et al. Nitrofurantoïn contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother 2013; 47(1):106-11
32. Cai T. et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis 2012; 55(6): 771-7
33. Cordero-Ampuero J. et al. Are antibiotics nesserary in hip arthroplasty with asymptomatique bacteriuria ? Seeding risk with/without treatment. Clin orthop relat Res 2013; 471(12): 3822-9
34. Sousa R. et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? Clin Infect Dis 2014; 59(1):41-7
35. Bingen E. et al. In vitro interaction between cefixime and amoxicillin-clavulanate against extended-sectrum-beta-lactamase-producing Escherichia coli causing urinary tract infection. J Clin Microbiol 2012; 50(7): 2540-1
36. Clerc O. et al. Traitement des infections urinaires simples: impact des résistances antibiotiques croissantes dans la communauté. Rev Med Suisse 2012 ; 8 : 878-81
37. Naber KG. et al. Antibiotic treatment of uncomplicated urinary tract infection in premenoposal women. Intern J Antimicrob Agents 2011; 38S: 21-35
38. Michalopoulos AS. et al. The revival of fosfomycin. Intern J infect Dis 2011; 15: e732-e739
39. Hutley EJ. et al. Fosfomycin: an oral agent for urinary infection caused by extensed spectrum beta-lactamase producing organism. J Infect 2010 doi:10.1016/j.jinfect.2010.01.006
40. Falagas ME. et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1862-77
41. Karageorgopoulos DE. et al. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antinicrob Chemother 2012; 67(2): 255-68
42. Tasbakan MI. et al. Nitrofurantoïne in the treatment of extensed-spectrum β-lactamase-producing Escherichia coli-related lower urinary tract infection. Intern J Antimicrob Agents 2012; 40: 554-6
43. Agence Française de sécurité Sanitaire des Produits de Santé (AFSSAPS). Nitrofurantoïne. Lettre aux professionnels de santé. http://www.infectiologie.com et http://ansm.sante.fr
44. Slekovec C. et al. When the precautionary principle disrupts 3 years of antibiotic stewardship: nitrofurantoïne in the treatment of urinary tract infections. J Antimicrob Chemother 2014; 69(1): 282-4
45. Cunha BA. et al. Nitrofurantoin: preferred empiric therapy for community-acquired lower urinary tract infections. Mayo Clin Proc 2011; 86(12): 1243-8
46. McKinnell JA. et al. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Payo clin Proc 2011; 86(6): 480-8
47. GeertsAFJ. et al. Ineffectiveness and adverse events of nitrofurantoïne in women with urinary tract infection and renal impairement in primary care. Eur J Clin Pharmacol 2013; 69(9): 1701-7
48. Cunha BA. Oral doxycycline for non-sytemic urinary tract infections (UTIs) due to P. aeruginosa and other Gram negative uropathogènes. Eur J Clin Microbiol Infect dis 2012; 31: 2865-68
49. Dewar S. et al. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother 2014; 69: 303-8
50. Jansaker F. et al. Clinical and bacteriological effects of pivmecillinam for EBLSE-producing Echerichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother 2014; 69 (3): 769-72
51. HAS. Commission de transparence. Selexid. avis du 3 avril 2014.
http://www.has-sante.fr/portail/jcms/c_412210/fr/commission-de-la-transparence
52. Rudenko N. et al. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycine trométamol. double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung 2005; 55 (7): 420-7
53. Singh KP. et al. Systemic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. Antimicrob Agents Chemother 2013; 57 (11): 5284-90
54. Zalmanovici TA. et al. Antimicrobial agents for treating uncomplicated urinary tract infection in women. The Cochrane Library 2010 issue 10 http://www.thecochranelibrary.com
55. van Hees BC. et al. Single-dose antibiotic prophylaxis for urinary catheter removal does not reduce the risk of urinary tract infection in surgical patients: a randomized double-blind placebo trial. Clin Microbiol Infect 2011; 17: 1091-4
56. Rowe TA. et al. Diagnosis and management of urinary tract infection in older adults. Infect Dis Clin N Am 2014; 28: 75-89
57. Nicolle LE. Urinary tract infection in special populations. diabetes, renal transplant, HIV infection, and spinal cord injury. Infect Dis Clin N Am 2014; 28: 91-104
58. Ivanov ML. et al. Bactériurie asymptomatique chez l’adulte: prise en charge différenciée. Rev Med Suisse 2008 ; 4 : 2452-6
59. Lipsky BA. et al. Treatment of bacterial prostatitis. Clin Infect Dis 2010; 50(12): 1641-52
60. Barbosa-Cesnick C. et al. Cranberry juice fails to prevent recurrent urinary tract infection:results from a randomized placebo-controlled trial. Clin infect Dis 2011; 52: 23-30
61. Stapelton AE. et al. Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo clin proc 2012; 87(2): 143-50
62. Jepson RG. et al. Cranberries for preventing urinary tract infections. Cochrane Database Syst rev 2012; 10: CD001321
63. Gbaguidi-Haore H. et al. Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a national multilevel study suggests differences with antibiotic classes. J antimicrob Chemother 2013; 68(2): 461-70
64. Vardakas KZ. et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriacae producing extended-spectrum β-lactamases: a systemic review and meta-analysis. J Antimicrob Chemother 2012; 67(12): 2793-803
65. Smithson A. et al. Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis 2012; 31: 423-30
66. Novo-Veleiro I. et al. paucisymptomatique infectious prostatitis as a cause of fever without an apparent origin. A series of 19 patients. Eur J Clin Microbiol Infect Dis 2013; 32: 263-8
67. Spoorenberg V. et al. Adequacy of an evidence-based treatment guideline for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence. Eur J Clin Microbiol Infect Dis 2013; 32: 1545-56
68. Graninger W. Pivmecillinam-Therapy of choise for lower urinary tract infection. Intern J Antimicrob Agents 2003; 22: S73-S78
69. Soraas A. et al. High rate of per oral mécillinam treatment failure in community-acquired urinary tract infections caused by EBLSE-producing Escherichia coli. Plos ONE 2014; 9(1): e85889
70. Lampri N. et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extensed-spectrum β-lactamase-producing Escherichia coli. J Antimicrob Chemother 2012; 67: 2424-28
71. Maraki S. et al. susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009; 53(10): 4508-10
72. Bruyère F. et al. Recommandations de bonnes pratiques cliniques: l’antibioprophylaxie en chirurgie urologique, par le Comité d’Infectiologie de l’Association Française d’Urologie. Progrès en Urologie 2010 ; 20 : 101-8
73. Pullukcu H. et al. Fosfomycin in the treatment of extensed spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Intern J Antimicrob Agents 2007 ; 29 : 62-5
74. Gardiner BJ. et al. Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis? Clin Infect Dis 2014; 58(4): e101-5
75. Van Duin D. Suppression of urinary tract infections with fosfomycine and trimethoprim-sulfamethoxazole: a case report. J Chemother 2011;23: 55-6
76. Lefort A. et al. Activity of fosfomycine alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase. Intern J Antimicrob Agents 2014; 43: 366-9
77. Raz R. Fosfomycin: an old-new antibiotic. Clin Infect dis 2012; 18: 4-7
78. Meyrier A. et al. Acute bacterial prostatis. Up To Date 06/03/2014 http://www.uptodate.com
79. Eliakim-Raz N. et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-7 days or less versus longer treatment: systemic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013; 68: 2183-91
80. Gagyor I. et al. Immediate versus conditional treatment of uncomplicated urinary tract-a randomized-controlled comparative effectiveness study in general practice. BMC Infect Dis 2012; 12: 146
81. Hooton TM. et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 625-63
82. Bonniaud V. et al. Prescrire des autosondages intermittents propres. Presse Med 2009 ; 38 : 392-6
83. Société de Pathologie Infectieuse de Langue Française (SPILF) et Association Française d’Urologie (AFU). Conférence de consensus. Infections urinaires nosocomiales de l'adulte. Paris 27 novembre 2002. Med Mal Inf 2003 ;33 (Suppl 4) 223 S -244 S
84. Salomon J. et al. Infection urinaire et vessie neurologique. Progrès en urologie 2007 ; 17 : 448-53
85. Lindgren PK. et al. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222-32
86. Sanders CC. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin Infect Dis 2001; 32(S1): S1-S8
87. Haute Autorité de Santé (HAS). Recommandations professionnelles Suivi et orientation des femmes enceintes en fonction des situations à risque identifiées. Mai 2007 http:// www.has-sante.fr
88. Hooton TM. et al. Urinary tract infections and asymptomatic bacteriuria in pregnancy Up To date 23/01/2015 http://www.uptodate.com
89. Centre de référence sur les agents tératogènes (lecrat) http://www.lecrat.org
90. Macejko AM. et al. Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. Urol Clin N Am 2007; 34: 35-42
91. SWAB guidelines for antimicrobial therapy of complicated urinary tract infections in adults. Mars 2013 http://www.swab.nl
92. Kazemier BM. et al. costs and effects of screening ant treating low risk women with a singleton pregnancy for asymptomatic bacteriuria, the ASB study. BMC Pregnancy Childbirth 2012; 12: 52
93. Smaill F. et al. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev 2009; (1): CD000490
94. Stapelton AE. Urinary tract infection pathogenesis: host factors. Infect Dis Clin N Am 2014; 28: 149-59
95. Grin PM et al. Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol 2013; 20(1):6607-14
96. Godaly G. et al. Innate immunity and genetic determinants of urinary tract infection susceptibility. Cur Opin Infect Dis 2015; 28: 88-96
97. O’Brien VP. et al. Are you experienced ? Understanding bladder innate immunity in the context of recurrent urinary tract infection. Cur Opin Infect Dis 2015; 28: 97-105
98. van der Starre WE. et al. Risks factors for fluoroquinonole-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother 2011; 66 (3): 650-6
99. Jeon JH. et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob Agents Chemother 2012; 56(6): 3043-6
100. Gruchalla RS. et al. Clinical practice. Antibiotic allergy. N Engl J Med 2006 ; 354(6): 601-9
101. Patterson TF. et al. Detection, signifiance, and therapy of bacteriuria in pregnancy. Update in the managementhealth care era. Infect Dis Clin N Am 1997; 11(3): 593-608
102. Vazquez JC. et al. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst rev 2011; (1): CD002256
103. Nordeng H. et al. Neonatal outcome after gestational exposure to nitrofurantoïne. Obstet Gynecol 2013; 121(2Pt1): 306-13
104. Usta TA. et al. Comparaison of single-dose and multiple-dose antibiotics for lower urinary tract infection in pregnancy. Int J Gynaecol Obstet 2011; 114(3): 229-33
105. Wing DA. et al. Pyelonephritis in pregnancy: treatment options for optimal outcomes. Drugs 2001; 61(14): 2087-96
106. Norgaard M. et al. Risk of miscarriage for pregnant users of pivmecillinam : a population-based case-control study. APMIS 2008; 116(4): 278-83
107. Vinter S. et al. Pivmecillinam and adverse birth and neonatal outcomes: a population-based cohort study. Scand J Infect dis 2004; 36(10): 733-7
108. Sanderson P. et al. Pivmecillinam for bacteriuria in pregnancy. Antimicrob Chemother 1894 ; 13(4) : 383-8
109. Larsen H. et al. Bith outcome and risk of neonatal hypoglycaemia following in utero exposure to pivmecillinam : a population-based cohort study with 414 exposed pregnancy. Scand J Infect dis 2001; 33(6): 439-44
110. Guinto VT. et al. Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. Cochrane database Syst rev 2010; (9): CD 007855
111. Schnarr J. et al. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur J Clin Invest 2008; 38(S2): 50-7
112. Krcmery S. et al. Treatment of lower urinary tract infection in pregnancy. Intern J Antimicrob Agents 2001; 17: 279-82
113. Crider KS. et al. Antimicrobialmedication use duting pregnancy and risk of bith defect : national birth defect prevention study. Arch Pediatr Adolesc Med 2009; 163:978
114. Jeyabalan A. et al. Anatomic and functional changes of the upper urinary tract during pregnancy. Urol Clin N Am 2007; 34:1-6
115. Anonyme. Synthèse élaborée par la redaction. Patientes enceintes ayant une infection urinaire. Rvue Prescrire 2013 ; 33(358) : 608-17
116. Isnard Bagnis C. et al Infections urinaires au cours de la grossesse. Rev Prat 2014 ; 64 : 983-5
117. Schneeberger C. et al. Intervention for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst Rev 2012; 11: CD009279
118. Anonyme. Rédaction Prescrire. Cystites simples chez la femme. Revue Prescrire 2014 ;34(369) : 528-30
119. Abbo L. et al. Antimicrobial stewardship and urinary tract infections. Antibiotics 2014; 3: 174-92
120. Bally F. Infection urinaire : un diagnostic sur mesure. rev Med Suisse 2008 ; 4 : 2145-8
121. Latini Keller V. et al. Analyse d’urine : l’ABC du praticien . Rev Med Suisse 2009 ; 5 : 1870-5
122. Sabeh N. et al. Symptômes urinaires bas et bandelette normale : à quoi penser ? Rev Med Suisse 2012 ; 8 : 1811-5
123. Wise GL et al. Sterile pyuria. N Engl J Med 2015 ; 372 : 1048-54
124. Raz R. et al. Chronic indwelling catheter replacement before antimicrobial therapy for symptomatic urinary tract infection. J Urol 2000; 164(4): 1254-8
125. Joshi A. et al. Regression of pyuria during the treatment of symptomatic urinary tract infection in patients with spinal cord injury. Spinal Cord 1996;34(12): 742-4
126. de Souza RM. et al. urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol 2008 ; 4(5) : 252-64
127. Green H. et al. Antibiotic prophylaxis for urinary tract infections in renal transplant recipients : a systematic review and meta-analysis. Transpl Infect Dis 2011; 13(5):441-7
128. Al-Hasan MN. et al. Impact of Gram-negative bloodstream infection on long-term allograft survival after kidney transplantation. Transplantation 2011; 13(5): 1206-10
129. Saemann M. et al. Urinary tract infection in renal transplant recipient. Eur J Clin Invest 2008; 38(Suppl2): 58-65
130. Pinherio HS. et al. Urinary tract infection caused by extensed-spectrum beta-lactamase-producing bacteria in kidney transplant patients. Transpl Proc 2010; 42(2): 486-7
131. Green H. et al. Consequences of treated versus untreated asymptomatique bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis 2013; 32(1): 127-31
132. Golebiewska J. et al. Urinary tract infection in renal transplant recipients. transpl Proc 2011; 43(8): 2985-90
133. Sallee M. et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4(7): 1183-9
134. Beerepoot MA. et al. Cranberries vs antibiotics to prevent urinaty tract infections: randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med 2011; 171(14): 1270-8
135. Perrotta C. et al. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst rev 2008; (2): cd005131
136. Stapleton AE. et al. randomized, placebo-controlled phase 2 trial of Lactobacillus crispaus probiotic given intravaginaly for prevention of recurrent urinary tract infection. Clin Infect Dis 2011; 52(10: 1212-7
137. Beerenpoot MA. et al. Lactobacilli vs antibiotics to prevent urinary tract infection: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med 2012; 172(9): 704-12
138. Mavromanolakis E. et al. Effect of norfloxacine, trimethoprim-sulfamethoxazole and nitrofurantoïne on fecal flora of women with recurrent urinary tract infection. J Chemother 1997; 9(3): 203-7
139. Chenoweth C. et al. Diagnosis, management, and prevention of catheter-associated urinary tract infections. Infect dis Clin N Am 2014; 28: 105-119
140. Dayts O. et al. Evidence-based protocol. Diagnosis and treatment of catheter-associated urinary tract infection within adult neurocritical care patient population. Nurs Clin N Am 2014; 49: 29-43
141. Nicolle LE. Urinary catheter-associated infections. Infect Clin N Am 2012; 26: 13-27
142. Sotto A. et al. Infections liées aux sondes urinaires. Rev Prat 2014 ; 64 : 651-55
143. Massa LM. et al. Validity, accurancy, and predictive value of urinary tract infection signs and symptoms in individuals with spinal cord injury on intermittent catheterization. J Spinal Cord Med 2008; 32(5): 568-63
144. Schumm K. et al. Types of uretral catheters for management of short-term voidingproblems in hospitalized adults. Cochrane Database Syst rev 2008; issue 2
145. Fink R. et al. Indwelling urinary catheter management and catheter-associated urinary tract infection prevention practice in nurses improving for healthsystem elders hospitals. Am J Infect Control 2012; 40: 715-20
146. Cariou G. et al. Comité d’infectiologie de l’Association française d’Urologie. Conduite à tenir en cas de colonisation d’une sonde à demeure par une bactérie multirésistante chez un futur opéré d’urologie. Résumé du Forum de CIAFU. Prog Urol – FMC 2011 ; 21 : F77-9
147. Hill TC. et al. Best practice for the treatment and prevention of urinary tract infection in the spinal cord injured population : the Alberta context. Can Urol Assoc J 2013; 7: 122-30
148. D’Hondt F. et al. Urinary tract infections in patients with spinal cord injuries. Curr Infect Dis Rep 2011; 13: 544-51
149. Opperman EA. et al. Cranberry is not effective for the prevention or treatment of urinary tract infections in individuals with spinal cord injury. Spinal cord 2010; 48: 451-6
150. Bermingham SL. et al. Intermittent sel catheterization with hydrophilic, gel reservoir, and non-coated catheters: a systemic review and cost effectiveness analysis. BMJ 2013; 346: e8639
151. Pannek J. et al. EAU guidelines on neurologic lower urinary tract dysfunction. http://uroweb.org/wp-content/uploads/20_Neurogenic-LUTD_LR.pdf
152. Pannek J. Treatment of yrinary tract infection in persons with spinal cord injury: guidelines, evidence, and clinical practice. J Spinal Cord Med 2011; 43(1): 11-5
153. Goetz LL. t al. International spinal cord injury tract infection basic data set. Spinal Cord 2013; 51: 700-4
154. Goetz LL. et al. Strategies for prevention of urinary tract infections in neurogenic bladder dysfunction. Phys Med Rehabil Clin N Am 2014; 25:605-18
155. Klausner A. et al. The neurogenic bladder: an update with management strategies for primary care physicians . Med Clin N Am 2011; 95: 111-20
156. Gormley EA. Urologic complication of the neurogenic bladder. Urol clin N Am 2010; 37: 601-7
157. Wyndaele JJ. et al. Clean intermittent catheterization and urinary tract infection: a review and guide for future research. BJU International 2012; 110: e910-7
158. Abrams GM. et al. Chronic complications of spinal cord injury and diseases. Up To date 15/07/2114; http://www.uptodate.com
159. Middleton J. et al. Management of the neurogenic bladder for adults with spinal cord injury. ACI. 3ème Ed 2014. http://www.aci.health.nsw.gov.au
160. Salomon J. Prevention of urinary tract infection in spinal cord-injured patients: safety and fefficacy of a weekly oralcyclic antibiotic 5WOCA) programme with a 2 years follow-up- an observational prospective study. J Antimicrob Chemother 2006; 57: 784-8
161. de Sèze M. Infection urinaire dans la sclérose en plaques : prévalence, facteur de risque et mode de gestion. Neurologie.com 2009 ;1(8) : 215-18
162. Botto H. et al. Infections urinaires nosocomiales de l’adulte : conférence de consensus 2002. Med Mal inf 2003 ; 33 : 370-5
163. Issad B. et al. Infections urinaires nosocomiales. Rev Prat 2014 ; 64 : 986-8
164. Neelakanta A. et al. Impact of changes in the NHSN catheter-associated urinary tract infection (CAUTI) surveillance criteria on the frequency and epidemiology of CAUTI in intensive care units. Infect Control Hosp Epidemiol 2015; 36(3): 34—9
165. Trautner B. Management of catheter-associated urinary tract infection. Curr Opin Infect Dis 2010; 23: 76-82
166. Fekete T. Catheter-associated urinary trct infection in adults. Up To date 01/08/2014. http://www.uptodate.com
167. Dielubanza EJ. et al. Management of non-catheter-associated complicated urinary tract infection. Infect Clin N Am 2014; 28: 121-34
168. Robertson TM. et al. Urodynamics. Crit care Nurs Clin N Am 2010 ; 22 : 109-20
169. Mirone V. et al. Clinical aspects of antimicrobial prphylaxis for invasive urological procedures. J Chemother 2014; 26(Suppl1): 1-13
170. Latthe PM. et al. Prophylactic antibiotics in urodynamics: a systemic review of effectiveness and safety. Neurol Urodyn 2008; 27: 167-73
171. Cundiff GW. et al. Randomized trail of antibiotic prophylaxis for combined urodynamics and cystouretheroscopy. Obstet Gynecol 1999; 93(Pt1): 749-52
172. Logadottir Y. et al. Invasive urodynamic studies are well tolerated by the patients and associated with a low risk of urinary tract infection. Scand J Urol Nephrol 2001; 35: 459-62
173. Concia E. et al. Therapeutic recommendations of the multidisciplinary group. J Chemother 2014; 26(Suppl1): 36-38
174. Concia E. et al. Aetiology and antibiotic resistance issues regarding urological procedures. J Chemother 2014; 26(Suppl1): 14-23
175. Foon R. et al. Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies. Cochrane Database Syst Rev 2012; CD008224
176. Dass AK. et al. Bacteriuria and safety of female urodynamic studies. Int Urogynecol J 2013; 24: 677-82
177. Choe JH. et al. Urodynamic studies in women with stress urinary incontinence: significant bacteriuria and risk factors. Neurourol Urodyn2007; 26(6): 847-51
178. Gray M. Preparing the patient for multichannel urodynamics testing. Urol Nurs 2011; 31(2):71-7
179. Gürbüz C. Are prophylactic antibiotics necessary for urodynamic study? Kaohsiung J Med Sci 2013;29(6): 325-9
180. Mrkobrada M. et al. CUA guidelines an antibiotic prophylaxis for urologic procedures. Can Urol Assoc J 2015; 9(1-2): 13-22
181. Estebanez A. et al. Fosfomycin in a single dose versus à 7 day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy. Eur J Clin Microbiol Infect dis 2009; 28(12): 1457-64
182. Matuszkiewicz J. et al. Urinary tract infections in pregnancy: old and new unresolved diagnosis and therapeutic problems. Arch Med Sci 2013; 11(1): 67-77
183. American College of Obstetricians and gynecologists. Sulfonamides, nitrofurantoïne, and risk of birth defects. Committee Opinion n°494. Obstet Gynecol 2011; 117: 1484-5
184. Bar-Oz B. et al. The safety ofquinolones-a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2009; 143: 75-8
185. Cunha BA. et al. The safety of nitrofurantoïne for the treatment of nosocomial catheter-associated bacteriuria (CAB) and cystitis. J Chemother 2015; 27(2): 122-3
186. Fraisse T. et al. Recommandations du comité d’infectiologie de l’AFU. Diagnostic, traitement et suivi des candiduries. Progrès en urologie 2011 ; 21 : 314-21
187. Keating GM. Fosfomycin trometamol : a review of its use as single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 2013;73: 1951-66
188. Workowski KA. et al. Sexually transmitted diseases treatment guidelines 2015. Center for Diseases Control and Prevention. MMWR 2015; 64 (3): 1-138
189. Commission de la Transparence. Negaban . Avis du 1 avril 2015. http://www.has-sante.fr
190. Touma NJ. et al. Prostatitis and chronic pelvic pain syndrome in men. Med Clin N Am 2011; 95:75-86
191. Buhr GT. et al.Urinary tract infections in long-term care residents. Clin Geriatr Med 2011; 27: 229-39
192. Tambyah PA. et al. Catheter-associated urinary tract infection. Curr Opin Infect Dis 2012; 25: 365-70
193. Chenoweth C. et al. Preventing catheter-associated urinary tract infections in the intensive care unit. Crit Care Clin 2013; 29: 19-32
194. Flores-Mireles AL. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature Rev 2015; 13: 269-84